Term
Didanosine
(ddI)/
Videx EC
(generic available; dose same as Videx EC) |
|
Definition
NRTI
Videx EC 125-, 200-, 250-, 400-mg capsules
Buffered tablets (non-EC) no longer available
Videx
10-mg/mL oral solution
Body weight ≥60kg:400 mg once daily*
With TDF: 250 mg once daily
Body weight <60kg:250 mg once daily*
With TDF: 200 mg once daily
Take 1/2 hour before or 2 hours after a meal
*Preferred dosing with oral solution is BID (total daily dose divided into 2 doses) |
|
|
Term
Emtricitabine
(FTC)/
Emtriva |
|
Definition
NRTI
Emtriva
-200-mg hard gelatin capsule
-10-mg/mL oral solution
Emtriva
Capsule: 200 mg once daily
Oral solution: 240 mg
(24 mL) once daily
Take without regard to meals
Also available as:Atripla (FTC 200 mg + EFV 600 mg + TDF 300 mg and Truvada (FTC 200 mg + TDF 300 mg) |
|
|
Term
|
Definition
NRTI
Ziagen
- 300-mg tablets
- 20-mg/mL oral solution
Ziagen
300 mg BID or
600 mg once daily
Take without regard to meals
Also available as: Epzicom (ABC 600 mg +
3TC 300 mg) and Trizivir(ABC 300 mg + ZDV 300 mg + 3TC 150 mg) |
|
|
Term
|
Definition
NRTI
Epivir
150-, 300-mg tablets
10-mg/mL oral solution
Epivir
150 mg BID or
300 mg once daily
Take without regard to meals
aLOS AVAILABLE AS: Combivir, Trizivir, and Epzicom |
|
|
Term
|
Definition
NRTI
Zerit
• 15-, 20-, 30-, 40-mg capsules
• 1-mg/mL oral solution
Body weight ≥60 kg:
40 mg BID
Body weight <60 kg:
30 mg BID*
Take without regard to meals
*WHO recommends 30 mg BID dosing regardless of body weight. |
|
|
Term
Tenofovir Disoproxil Fumarate (TDF)/
Viread |
|
Definition
NRTI
Viread
300-mg tablet
Viread
1 tablet once daily
Take without regard to meals |
|
|
Term
Zidovudine
(ZDV)/
Retrovir (generic available; dose same as retrovir) |
|
Definition
NRTI
Retrovir
• 100-mg capsules
• 300-mg tablets
• 10-mg/mL intravenous solution
• 10-mg/mL oral solution
Retrovir
300 mg BID or
200 mg TID
Take without regard to meals |
|
|
Term
| Delavirdine (DLV)/ Rescriptor |
|
Definition
nnrti
100-, 200-mg tablets
400 mg TID (Four 100-mg tablets can be dispersed in >3 oz. of water to produce a slurry; 200-mg tablets should be taken as intact tablets.) |
|
|
Term
|
Definition
NNRTI
• 50-, 200-mg capsules
• 600-mg tablets
600 mg once daily at or before bedtime
Take on an empty stomach to reduce side effects |
|
|
Term
| Etravirine (ETR)/ Intelence |
|
Definition
NNRTI
• 100-mg tablets
• 200-mg tablets
200 mg BID
Take following a meal |
|
|
Term
| Nevirapine (NVP)/ Viramune |
|
Definition
NNRTI
• 200-mg tablets
• 50-mg/5-mL oral suspension
200 mg once daily for 14 days (lead-in period); thereafter, 200 mg BID Take without regard to meals
Repeat lead-in period if therapy is discontinued for >7 days
In patients who develop mild to moderate rash without constitutional symptoms, continue lead-in period until rash resolves but no longer than 28 days total. |
|
|
Term
| Atazanavir (ATV)/ Reyataz |
|
Definition
PI
100-, 150-, 200-, 300-mg capsules
ARV-naïve patients:
400 mg once daily or (ATV 300 mg + RTV 100 mg) once daily
With TDF or for ARV-experienced patients:
(ATV 300 mg + RTV 100 mg) once daily
With EFV in ARV-naïve patients:
(ATV 400 mg + RTV 100 mg) once daily |
|
|
Term
| Darunavir (DRV)/ Prezista |
|
Definition
PI
75-, 150-, 300-, 400-, 600-mg tablets
ARV-naïve patients or ARV-experienced patients with no DRV mutations:
(DRV 800 mg + RTV 100 mg) once daily
ARV-experienced patients with at least one DRV mutation:
(DRV 600 mg + RTV 100 mg) BID
Unboosted DRV is not recommended |
|
|
Term
Fosamprenavir (FPV)/
Lexiva (a prodrug of amprenavir [APV]) |
|
Definition
PI
• 700-mg tablet
• 50-mg/mL oral suspension
ARV-naïve patients:
• FPV 1,400 mg BID or
• (FPV 1,400 mg + RTV 100–200 mg) once daily or
• (FPV 700 mg + RTV 100 mg) BID
PI-experienced patients (once-daily dosing not recommended):
•(FPV 700 mg + RTV 100 mg) BID
With EFV:
• (FPV 700 mg + RTV 100 mg) BID or
• (FPV 1,400 mg + RTV 300 mg) once daily
Tablet: Take without regard to meals (if not boosted with RTV tablet)
Suspension: Take without food
FPV w/RTV tablet: Take with meals |
|
|
Term
|
Definition
PI
100-, 200-, 400-mg capsules
800 mg every 8 hrs
Take 1 hour before or 2 hours after meals; may take with skim milk or low-fat meal
With RTV:
(IDV 800 mg + RTV 100–200 mg) BID |
|
|
Term
Lopinavir + Ritonavir (LPV/r)/
Kaletra |
|
Definition
PI
Tablets:
(LPV 200 mg + RTV 50 mg) or
(LPV 100 mg + RTV 25 mg)
Oral solution: Each 5 mL contains (LPV 400 mg + RTV 100 mg)
Oral solution contains 42% alcohol
LPV/r 400-mg/100-mg BID
or
LPV/r 800-mg/200-mg once daily |
|
|
Term
| Nelfinavir (NFV)/ Viracept |
|
Definition
PI
250-, 625-mg tablets
• 50-mg/g oral powder
1,250 mg BID or
750 mg TID
May dissolve tablets in a small amount of water; once dissolved, patients should mix the cloudy liquid well and consume it immediately. |
|
|
Term
|
Definition
PI
• 100-mg soft gel capsules
• 100-mg tablets
• 80-mg/mL oral solution
Oral solution contains 43% alcohol
As pharmacokinetic booster for other PIs: 100–400 mg per day in 1–2 divided doses |
|
|
Term
Saquinavir tablets and hard gel capsules
(SQV)/ Invirase |
|
Definition
PI
500-mg tablets
• 200-mg hard gel capsules
(SQV 1,000 mg + RTV 100 mg) BID
Unboosted SQV is not recommended. |
|
|
Term
| Tipranavir (TPV)/ Aptivus |
|
Definition
PI
• 250-mg capsules
• 100-mg/mL oral solution
(TPV 500 mg + RTV 200 mg) BID
Unboosted TPV is not recommended. |
|
|
Term
| Raltegravir (RAL)/ Isentress |
|
Definition
Integrase Inhibitor
400 mg tablets
400 mg BID
With rifampin: 800 mg BID |
|
|
Term
| Enfuvirtide (T20)/ Fuzeon |
|
Definition
Fusion Inhibitor
• Injectable—supplied as lyophilized powder
• Each vial contains 108 mg of T20; reconstitute with 1.1mL of sterile water for injection for delivery of approximately 90mg/1mL.
90 mg (1mL) subcutaneously BID |
|
|
Term
| Maraviroc (MVC)/ Selzentry |
|
Definition
CCR5 Antagonist
150-, 300-mg tablets
• 150 mg BID when given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r)
• 300 mg BID when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
• 600 mg BID when given with CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) |
|
|
Term
| WHY IS SUSTIVA GIVEN A BEDTIME? |
|
Definition
|
|
Term
| WHAT ALLOWS THE FREE HIV TO BIND TO CELL |
|
Definition
|
|
Term
| PREVENT HIV GENETIC MATERIAL FROM INTEGRATING INTO CD4 CELL, THUS STOPPING VIRAL REPLICATION |
|
Definition
INTEGRASE INHIBITOR
ISENTRESS (raltegravir) |
|
|
Term
| bind tightly to reverse transcriptase which prevent viral RNA from converting to viral DNA |
|
Definition
|
|
Term
| Prevents the enzyme protease from cutting the virus into shorter pieces that it needs to make copies of itself |
|
Definition
| Protease Inhibitors (PIs) |
|
|
Term
| Work by incorporating itself into viral DNA, MAKING IT INEFFECTIVE |
|
Definition
|
|
Term
| Prevents entry into CD4 cells |
|
Definition
Entry Inhibitors
Fuzeon (enfuvirtide)
Maraviroc (Selzentry) |
|
|
Term
|
Definition
| Used for boosting other PIs b/c it is a potent inhibitor of CYP3A4 |
|
|
Term
| HOW SHOULD RITONAVIR CAPSULES AND TABLETS BE STORED? |
|
Definition
CAPSULES-REFRIGERATED
TABLETS -SHELF |
|
|
Term
|
Definition
| Kaletra, Reyataz, Darunavir, Fosamprenavir |
|
|
Term
|
Definition
Hepatotoxicity
pancreatitis
peripheral neuropathy
lactic acidosis
hyperglycemia
hyperlipidemia
lipodystrophy (weight loss or weight gain)
N/V & diarrhea
Dermatologic rxn |
|
|
Term
| Level for undetectable viral load |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Symptoms of acute HIV infx |
|
Definition
muscle aches
lymphatenopathy
fever of unkown origin
flu-like sx |
|
|
Term
| What CD4 level does opportunistic infx occur |
|
Definition
|
|
Term
| Tests used to confirm HIV |
|
Definition
ELISA (enzyme-linked immunosorbent assay)
Western Blot |
|
|
Term
| Monitoring therapy/tests for ALL HIV patients |
|
Definition
|
|
Term
|
Definition
SEXUAL
PARENTERAL
PERINATAL (VERTICAL TRANSMISSION) |
|
|
Term
| What test should be done before ABC can be given |
|
Definition
|
|
Term
| Normal ALT and AST values |
|
Definition
ALT =5-40 U/L
AST 5-30 U/L |
|
|
Term
| Hepatotoxicity can occur within how many weeks of nevirapine(Viramune) therapy? |
|
Definition
|
|
Term
| Hepatotoxicity can occur within how many weeks of nevirapine(Viramune) therapy? |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Lactic Acidosis with hepatic steatosis |
|
|
Term
| Why should Simvastatin never be used with PIs |
|
Definition
| Levels of simvastatin increase by 400 % |
|
|
Term
| Term for WBC in the urine |
|
Definition
|
|
